EPIDEMIOLOGICAL AND HUMANISTIC BURDEN OF CUTANEOUS T‐CELL LYMPHOMAS: RESULTS OF a SYSTEMATIC REVIEW
Mehul Dalal(Takeda (United States)), Ashish Gautam(Sarojini Naidu Medical College), Erin Zagadailov(AbbVie (United States)), Conor McCloskey, Susie Mitchell(Kleijnen Systematic Reviews (United Kingdom))
Cited by 4
Related Papers
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
American Sign Language recognition using Support Vector Machine and Convolutional Neural Network
|International Journal of Information Technology|2021|64
Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial
|The Lancet Haematology|2022|49
Validation of the LC-MS/MS method for the quantification of mevalonic acid in human plasma and determination of the matrix effect
|Journal of Lipid Research|2006|34
Guggulsterone, a farnesoid X receptor antagonist lowers plasma trimethylamine- <i>N</i> -oxide levels: An evidence from in vitro and in vivo studies
|Human & Experimental Toxicology|2018|25